Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, referred to as “Astellas”) has received notification from the U.S. Food and Drug Administration (FDA) regarding the acceptance of the company’s supplemental New Drug Application (sNDA). This acceptance pertains to…
Bristol Myers Squibb (NYSE: BMY) has announced the successful results of the pivotal Phase 3 KRYSTAL-12 study, which evaluated KRAZATI® (adagrasib) as a monotherapy for patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring a…
Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has given approval for sotatercept-csrk, branded as WINREVAIR™ in the U.S., for injection in 45mg and 60mg doses. This…
AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) have announced a definitive agreement today, wherein AbbVie will acquire Landos, a clinical stage biopharmaceutical company primarily focused on developing novel oral therapeutics for patients with autoimmune diseases.…
Novo Nordisk has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion, recommending the marketing authorization for Awiqli® (the branded name for once-weekly basal insulin icodec) for the treatment of…
Novartis Unveils Positive CHMP Endorsement for Fabhalta® in Treating Paroxysmal Nocturnal Hemoglobinuria (PNH) Novartis has disclosed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a favorable opinion, recommending the authorization…
Today, it was announced that Ono has initiated a comprehensive collaboration for drug discovery with the University of Oxford in Oxfordshire, UK. This collaboration aims to explore and validate drug discovery seeds, as well as to obtain screening compounds to…
UCB, a leading global biopharmaceutical company, has announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a favorable opinion, recommending the granting of marketing authorization for BIMZELX® (bimekizumab) within…
Viatris Inc. recently concluded agreements for a comprehensive global research and development collaboration with Idorsia Ltd (SIX: IDIA), a transaction that was finalized on March 15, 2024. For detailed information regarding this significant transaction, please consult Viatris’ Annual Report on…
CRISPR Therapeutics, a leading biopharmaceutical firm dedicated to pioneering gene-based treatments for severe illnesses, has unveiled its proposal to appoint Christian Rommel, Ph.D., to its Board of Directors during the upcoming annual general meeting. Samarth Kulkarni, Ph.D., CEO and Chairman…
Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has revealed that Jannie Oosthuizen, President of Human Health U.S., is set to engage in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on…
AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, have announced a strategic partnership aimed at developing OSE-230, a monoclonal antibody designed to address chronic and severe inflammation. Currently in the pre-clinical development…